Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXEL
  • CUSIP: 30161Q10
  • Web: www.exelixis.com
  • Market Cap: $7.99 billion
  • Outstanding Shares: 293,904,000
Average Prices:
  • 50 Day Moving Avg: $26.26
  • 200 Day Moving Avg: $24.14
  • 52 Week Range: $10.04 - $32.50
  • Trailing P/E Ratio: 137.22
  • Foreward P/E Ratio: 40.55
  • P/E Growth: 2.13
Sales & Book Value:
  • Annual Revenue: $319.67 million
  • Price / Sales: 24.98
  • Book Value: $0.51 per share
  • Price / Book: 53.27
  • EBITDA: $95.32 million
  • Net Margins: 17.83%
  • Return on Equity: 52.80%
  • Return on Assets: 12.84%
  • Current Ratio: 4.12%
  • Quick Ratio: 4.06%
  • Average Volume: 3.82 million shs.
  • Beta: 1.91
  • Short Ratio: 4.61

Frequently Asked Questions for Exelixis (NASDAQ:EXEL)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Wednesday, August, 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The company earned $99.01 million during the quarter, compared to analyst estimates of $85.27 million. Exelixis had a net margin of 17.83% and a return on equity of 52.80%. The firm's quarterly revenue was up 173.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.15) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

12 brokers have issued 12 month target prices for Exelixis' shares. Their predictions range from $26.00 to $39.00. On average, they expect Exelixis' stock price to reach $31.29 in the next year. View Analyst Ratings for Exelixis.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. According to Zacks Investment Research, "Exelixis received a significant boost with the approval of the tablet formulation of cabozantinib, (distinct from the capsule form) under the brand name Cabometyx for the treatment of RCC in patients. New patient starts, refills for patients already on therapy and continued expansion of the prescriber base for Cabometyx are driving the drug’s sales. Meanwhile, Exelixis is developing cabozantinib in a broad development program and hassubmitted a supplemental New Drug Application (sNDA) for advanced RCC. The FDA assigned a PDUFA action date of Feb 15, 2018. A potential label expansion of Cabometyx will significantly boost the growth prospects. Exelixis also has collaborations with Bristol-Myers and Roche on the development of the drug in combination with immunotherapy agents. Moreover, Exelixis’ share price has outperformed the industry year to date. However, the company is heavily dependent on Cabometyx for growth." (10/18/2017)
  • 2. Cann analysts commented, "Exelixis, Inc. announced today that FDA has granted Priority Review of its supplemental New Drug Application (sNDA) for Cabometyx (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC). FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2018. We have modeled that Cabometyx will expand into the front-line RCC setting by 2019, but based on the timing of the PDUFA date for this indication, we now believe it could happen sooner." (10/16/2017)

Are investors shorting Exelixis?

Exelixis saw a increase in short interest in the month of September. As of September 29th, there was short interest totalling 19,986,804 shares, an increase of 8.2% from the September 15th total of 18,464,387 shares. Based on an average daily volume of 3,898,368 shares, the days-to-cover ratio is currently 5.1 days. Currently, 7.1% of the shares of the company are short sold.

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
  • Patrick Haley, Senior Vice President - Commercial
  • Charles M. Cohen Ph.D., Independent Director
  • Carl B. Feldbaum Esq., Independent Director
  • Alan M. Garber M.D. Ph.D., Independent Director

Who owns Exelixis stock?

Exelixis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (5.93%), Meeder Asset Management Inc. (0.01%) and Fisher Asset Management LLC (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $27.17.

MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $31.29 (15.15% upside)
Consensus Price Target History for Exelixis (NASDAQ:EXEL)
Price Target History for Exelixis (NASDAQ:EXEL)
Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $33.00N/AView Rating Details
10/17/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$33.00 -> $39.00N/AView Rating Details
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
10/16/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
10/16/2017SunTrust Banks, Inc.Boost Price TargetBuy -> Buy$32.00 -> $35.00N/AView Rating Details
10/16/2017CannReiterated RatingHoldN/AView Rating Details
9/22/2017Leerink SwannDowngradeOutperform -> Market Perform$34.00 -> $28.00HighView Rating Details
8/10/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche Bank AGDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
7/27/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Exelixis (NASDAQ:EXEL)
Earnings by Quarter for Exelixis (NASDAQ:EXEL)
Earnings History by Quarter for Exelixis (NASDAQ EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.05N/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.13
2018 EPS Consensus Estimate: $0.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20174$0.01$0.03$0.02
Q3 20174$0.05$0.07$0.07
Q4 20174$0.04$0.08$0.06
Q1 20181$0.09$0.09$0.09
Q2 20181$0.10$0.10$0.10
Q3 20181$0.15$0.15$0.15
Q4 20181$0.25$0.25$0.25
(Data provided by Zacks Investment Research)


Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.20%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Gisela SchwabInsiderSell100,000$23.79$2,379,000.00View SEC Filing  
9/28/2017Jeffrey HessekielEVPSell27,302$24.28$662,892.56View SEC Filing  
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Loading headlines, please wait.



Exelixis (EXEL) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.